Table 2

HbA1c testing frequency and patient distributions by adherence level

LowModerateHigh
(n=1928)(n=2411)(n=2085)
HbA1c tests, median (IQR)
 Performed during study period5 (4–7)8 (7–10)11 (11–13)
Age at baseline, mean (SD)
 Age, year65.3 (11.9)66.7 (11.1)68.0 (10.6)
Gender, n (%)
 Female920 (47.7)1103 (45.7)991 (47.5)
 Male1008 (52.3)1308 (54.3)1094 (52.5)
SES at baseline, n (%)
 1 (most disadvantaged)295 (15.3)342 (14.2)267 (12.8)
 2236 (12.2)265 (11.0)169 (8.1)
 3423 (21.9)506 (21.0)509 (24.4)
 4354 (18.4)499 (20.7)403 (19.3)
 5 (most advantaged)620 (32.2)799 (33.1)737 (35.3)
Remoteness at baseline, n (%)
 Major cities1582 (82.1)1941 (80.5)1620 (77.7)
 Regional/remote346 (17.9)470 (19.5)465 (22.3)
Medication at baseline, n (%)
 Insulin246 (12.8)355 (14.7)289 (13.9)
 Oral agents only1091 (56.6)1409 (58.4)1234 (59.2)
 No medication591 (30.7)647 (26.8)562 (27.0)
Complications developed during study period, n (%)
 Chronic kidney disease38 (2.0)89 (3.7)80 (3.8)
 Ischaemic heart disease11 (0.6)21 (1.1)20 (1.0)
  • HbA1c, glycated haemoglobin A1c; IQR, interquartile range ; SD, standard deviation; SES, socioeconomic status.